Zobrazeno 1 - 10
of 87
pro vyhledávání: '"M, Stabl"'
Publikováno v:
International Clinical Psychopharmacology. 12:183-194
An international, multicenter, placebo-controlled study was undertaken to determine the safety and antidepressant efficacy of moclobemide, a new reversible inhibitor of monoamine oxidase A, and imipramine in the treatment of dysthymia (DSM-III-R). A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff64bfd303ccf44d445900db0de9271d
https://doi.org/10.1097/00004850-199707000-00001
https://doi.org/10.1097/00004850-199707000-00001
Publikováno v:
Acta Psychiatrica Scandinavica. 92:260-265
The efficacy and the safety of moclobemide (400-600 mg/day), a reversible and selective inhibitor of monoamine oxidase-A (RIMA) and of clomipramine (100-150 mg/day) were compared respectively in 98 and 93 nonmelancholic, nonpsychotic out-patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b31ca74ed910e0c1f0b1e94f6d0918ff
https://doi.org/10.1111/j.1600-0447.1995.tb09580.x
https://doi.org/10.1111/j.1600-0447.1995.tb09580.x
Publikováno v:
Clinical Neuropharmacology. 17:S74-S87
Safety aspects [adverse events, blood pressure and heart rate, weight, and laboratory tests (liver parameters, hemoglobin, leukocytes)] of long-term treatment in 1,120 patients are discussed. Adverse events during this long-term treatment were also c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b768a575445ca503396143d11389c20
https://doi.org/10.1097/00002826-199417001-00009
https://doi.org/10.1097/00002826-199417001-00009
Publikováno v:
Pharmacopsychiatry. 26:240-245
Moclobemide is the first of a new generation of reversible inhibitors of monoamine oxidase-A (RIMA) with no clinically relevant potentiation of the hypertensive actions of dietary tyramine. The present study was conducted to compare the efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a93fd4796be241a8d6ac348679ed08f5
https://doi.org/10.1055/s-2007-1014361
https://doi.org/10.1055/s-2007-1014361
Publikováno v:
Human Psychopharmacology: Clinical and Experimental. 8:311-317
In a meta-analysis of short-term (four weeks) trials of antidepressants, two response criteria were compared separately for low- ( 28) scores on the 17-item version of the Hamilton Rating Scale for Depression: (HAMD-17): (a) 50 per cent reduction of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efc3c60eb62f1d799c6a96093bbc4fec
https://doi.org/10.1002/hup.470080503
https://doi.org/10.1002/hup.470080503
Publikováno v:
International Clinical Psychopharmacology. 7:123-132
Moclobemide, a specific reversible inhibitor of monoamine oxidase that shows a preference for the A isoenzyme, has been developed as a new antidepressive agent. Unlike earlier generation monoamine oxidase inhibitors, moclobemide is devoid of any clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be1f2f16ea847e0e7ffc3c8b4ff1a842
https://doi.org/10.1097/00004850-199300730-00001
https://doi.org/10.1097/00004850-199300730-00001
Publikováno v:
Psychopharmacology. 106:S24-S31
Interactions may occur on pharmacological or pharmacokinetic grounds. Both types of interactions are discussed in relationship with the pharmacological and pharmacokinetic data of moclobemide, a reversible MAO-inhibitor. A variety of interaction stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b92d1d990913577f3bc7e5cde1e64e02
https://doi.org/10.1007/bf02246229
https://doi.org/10.1007/bf02246229
Publikováno v:
Acta Psychiatrica Scandinavica. 82:24-28
Moclobemide, a new selective and reversible inhibitor of monoamine oxidase A (RIMA), has been compared with various tricyclic antidepressants (TCAs) in numerous controlled studies. Pooled data from these studies, comprising 1656 patients, as well as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5df9aa56e8e0bb57f954b6bebfea107
https://doi.org/10.1111/j.1600-0447.1990.tb05320.x
https://doi.org/10.1111/j.1600-0447.1990.tb05320.x
Publikováno v:
Psychopharmacology. 106:S120-S122
Evaluation of 247 patients receiving long-term moclobemide treatment showed that it was effective as an antidepressant, as measured both by decrease in HAMD mean total score and the doctor's evaluation of therapeutic effect. In patients who had been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59e42252b14f6ffb3fbb7dbfe2f2e64f
https://doi.org/10.1007/bf02246254
https://doi.org/10.1007/bf02246254
Publikováno v:
International clinical psychopharmacology. 12(4)
An international, multicenter, placebo-controlled study was undertaken to determine the safety and antidepressant efficacy of moclobemide, a new reversible inhibitor of monoamine oxidase A, and imipramine in the treatment of dysthymia (DSM-III-R). A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a9ffea21a689de59e9119cdee3d369a2
https://pubmed.ncbi.nlm.nih.gov/9347378
https://pubmed.ncbi.nlm.nih.gov/9347378